Who makes Lidocaine with 1:200,000 epinephrine solution?

Lidocaine with 1:200,000 epinephrine solution is developed by Hull University Teaching Hospitals NHS Trust.

What development phase is Lidocaine with 1:200,000 epinephrine solution in?

Lidocaine with 1:200,000 epinephrine solution is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Lidocaine with 1:200,000 epinephrine solution

Hull University Teaching Hospitals NHS Trust · FDA-approved active Small molecule Quality 0/100

Lidocaine with 1:200,000 epinephrine solution, marketed by Hull University Teaching Hospitals NHS Trust, holds a position in the local anesthetic market. The key composition patent expires in 2028, providing a period of exclusivity that supports market stability. The primary risk is the lack of reported revenue and key trial results, which may limit investor confidence and market expansion.

At a glance

Generic name	Lidocaine with 1:200,000 epinephrine solution
Also known as	Lignocaine with 1:200,000 adrenaline solution
Sponsor	Hull University Teaching Hospitals NHS Trust
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

TAP Block for Open Radical Prostatectomy. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results